Response Genetics, Inc (RGDXQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 4.46: the stock has moved about 346% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerResponse Genetics, Inc (RGDXQ) trades at $0.0001. Response Genetics, Inc. is a life sciences company specializing in pharmacogenomic tests to guide cancer treatment decisions across various tumor types. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for RGDXQ: RGDXQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Response Genetics, Inc (RGDXQ) Healthcare & Pipeline Overview
Response Genetics, Inc. is a life sciences firm established in 1999, focused on developing and commercializing pharmacogenomic tests for cancer treatment guidance. The company offers a comprehensive suite of diagnostic services for multiple cancer types, serving healthcare providers and pharmaceutical enterprises across the United States and Europe.
What Is the Investment Thesis for RGDXQ?
Response Genetics, Inc. historically positioned itself within the personalized medicine segment of oncology, focusing on pharmacogenomic tests to guide cancer treatment. The company's business model, centered on diagnostic services and interpretations for multiple cancer types, addresses a critical need for precision in oncology. However, the company's current financial profile, marked by a negative profit margin of -111.9% and a gross margin of 21.9%, indicates significant operational challenges. Its market capitalization is reported as $0.00 billion, suggesting a minimal or distressed valuation. The stock's classification on the OTC Other tier further highlights substantial risks, often associated with financial distress, limited public disclosure, and potential regulatory issues. While the company's historical focus on a growing healthcare area like personalized diagnostics presents a theoretical value driver, the current operational and financial context necessitates careful scrutiny of any potential restructuring or business model changes for future viability.
Based on FMP financials and quantitative analysis
RGDXQ Key Highlights
Market Capitalization reported as $0.00 billion, indicating a minimal or distressed valuation.
- Profit Margin of -111.9% reflects significant net losses relative to revenue.
- Gross Margin stands at 21.9%, suggesting challenges in covering operational costs beyond direct production.
- Beta of 4.46 indicates high volatility compared to the broader market.
- The company employs 96 individuals, contributing to its operational capacity in diagnostics.
What Are RGDXQ's Key Strengths?
Specialized focus on pharmacogenomic testing for personalized cancer treatment.
- Comprehensive ResponseDX test suite covering multiple cancer types.
- Global operational presence in the United States and Europe.
- Integrated service offering includes both technical execution and professional interpretation.
- Direct sales force enables targeted client engagement.
What Are RGDXQ's Weaknesses?
Significant negative profit margin of -111.9% indicates substantial unprofitability.
- Gross margin of 21.9% suggests limited profitability from core services.
- Market capitalization reported as $0.00 billion, implying severe financial distress.
- OTC Other listing indicates heightened financial risk and potential regulatory issues.
- High Beta of 4.46 suggests extreme stock price volatility.
What Are the Key Risks for RGDXQ?
Financial-distress signal — its Altman Z-Score of -12.84 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- The 'OTC Other' listing signifies substantial financial distress and potential regulatory issues, including the risk of further delisting or cessation of trading.
- A negative profit margin of -111.9% indicates significant unprofitability, raising concerns about the company's long-term financial viability and ability to sustain operations.
- Extremely low market capitalization and trading volume suggest severe illiquidity, making it challenging for investors to exit positions without significant price impact.
- Lack of transparent financial disclosures, due to its OTC Other status, creates significant information asymmetry and hinders informed investment decisions.
- The high Beta of 4.46 indicates extreme price volatility, exposing investors to substantial and rapid fluctuations in stock value.
What Threats Does RGDXQ Face?
- Intense competition from larger, well-funded diagnostic companies.
- Rapid technological obsolescence in the fast-evolving field of genomics.
- Regulatory hurdles and reimbursement challenges for novel diagnostic tests.
- Financial distress and potential delisting associated with OTC Other status.
- Economic downturns impacting healthcare spending and diagnostic test adoption.
What Are RGDXQ's Competitive Advantages?
- Specialized expertise in pharmacogenomics, focusing on cancer treatment response prediction.
- Proprietary ResponseDX suite of tests covering multiple cancer types.
- Integrated service model providing both technical execution and professional interpretation.
- Established global presence with operations in the United States and Europe.
- Direct sales force reaching diverse client segments including oncologists and pharmaceutical companies.
What Does RGDXQ Do?
Response Genetics, Inc., originally founded as Bio Type, Inc. in Los Angeles, California, in 1999, rebranded in August 2000 to focus on the burgeoning field of pharmacogenomics. The company's core mission revolves around creating, advancing, and commercializing specialized diagnostic tests that are pivotal in informing cancer treatment decisions. These sophisticated tools analyze specific indicators within tumor tissue samples, providing crucial insights into how a patient is likely to respond to various therapies. Through its flagship ResponseDX suite, Response Genetics offers an extensive array of testing services tailored for a wide spectrum of cancers, including non-small cell lung, colorectal, gastric, gastroesophageal, melanoma, thyroid, breast, and glioma. Additionally, the company provides a specialized Tissue of Origin test, aiding in the precise identification of cancer sources. Beyond its current offerings, Response Genetics maintains a strategic commitment to broadening its diagnostic portfolio to encompass an even wider range of tumor types. The company's service model is comprehensive, encompassing both the technical execution of its advanced testing procedures and the professional interpretation of the results, ensuring actionable insights for clinicians. Operating with a global footprint, Response Genetics has established a significant presence across both the United States and Europe. Its diverse client base includes community oncologists, pathologists, various medical practices, hospitals, and pharmaceutical enterprises, all served primarily through its dedicated internal sales force.
What Products and Services Does RGDXQ Offer?
- Develops and commercializes pharmacogenomic tests for cancer treatment decisions.
- Assesses specific indicators in tumor tissue samples to predict patient response to therapy.
- Offers an extensive suite of ResponseDX testing services for various cancers.
- Provides diagnostic tests for non-small cell lung, colorectal, gastric, melanoma, thyroid, breast, and glioma cancers.
- Includes a Tissue of Origin test to identify the primary source of cancer.
- Committed to expanding its diagnostic offerings to cover additional tumor types.
- Delivers both the technical execution and professional interpretation of its testing services.
- Operates globally, with a significant presence in the United States and Europe.
How Does RGDXQ Make Money?
- Generates revenue by providing pharmacogenomic testing services to healthcare providers and pharmaceutical companies.
- Offers a suite of proprietary ResponseDX tests, which are sold as diagnostic tools.
- Charges for both the technical laboratory analysis of tumor tissue samples and the professional interpretation of the results.
- Utilizes an internal sales force to market and distribute its testing services to a diverse client base.
- Focuses on a fee-for-service model for its diagnostic solutions in oncology.
What Industry Does RGDXQ Operate In?
Response Genetics, Inc. operates within the highly specialized and evolving Medical - Diagnostics & Research industry, specifically focusing on pharmacogenomics in oncology. This segment is characterized by rapid scientific advancements and a growing demand for personalized medicine approaches. The broader healthcare sector is experiencing a significant shift towards precision diagnostics, where genetic and molecular insights guide therapeutic decisions, aiming for improved patient outcomes and reduced healthcare costs. The competitive landscape includes large diagnostic companies, specialized biotech firms, and academic institutions, all vying for market share in cancer diagnostics. Response Genetics' position is defined by its array of ResponseDX tests for various cancers, serving a diverse client base in the U.S. and Europe. However, operating on the OTC Other tier suggests a challenging competitive and financial environment, contrasting with the high-growth potential often associated with advanced diagnostic technologies.
Who Are RGDXQ's Key Customers?
- Community oncologists seeking personalized treatment insights.
- Pathologists requiring advanced diagnostic tools for tumor analysis.
- Medical practices and hospitals utilizing pharmacogenomic testing for patient care.
- Pharmaceutical enterprises interested in companion diagnostics or clinical trial support.
- Healthcare providers in the United States and Europe.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Response Genetics, Inc operates in the Healthcare sector. It is headquartered in Los Angeles, United States.
Key Financial Metrics
Return on assets is -41.3%, showing how much profit it generates from its asset base. A current ratio of 2.86 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Response Genetics, Inc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.84 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Response Genetics, Inc has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 46.5% below estimates on average.
RGDXQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RGDXQ Latest News
No recent news available for RGDXQ.
RGDXQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RGDXQ.
Price Targets
Wall Street price target analysis for RGDXQ.
RGDXQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RGDXQ; grades run from A+ (80-100) to F (below 30).
Leadership: Thomas Bologna
CEO
Thomas Bologna serves as the CEO of Response Genetics, Inc., overseeing the company's strategic direction and operations. His leadership is critical in navigating the complex landscape of the life sciences and diagnostic industry. With 96 employees under his management, Bologna is responsible for steering the company's efforts in developing, advancing, and commercializing pharmacogenomic tests. His role encompasses ensuring the delivery of high-quality diagnostic services and interpretations to a global client base, including community oncologists, hospitals, and pharmaceutical enterprises. Bologna's background likely includes extensive experience in healthcare management, biotechnology, or diagnostics, given the specialized nature of Response Genetics' business.
Track Record: Under Thomas Bologna's leadership, Response Genetics has continued its focus on pharmacogenomic testing for cancer treatment decisions. His tenure has involved managing the company's global operations, particularly its presence in the United States and Europe. Key strategic decisions would have included the ongoing commitment to expanding diagnostic offerings to new tumor types and maintaining the integrated service model of technical execution and professional interpretation. Bologna's leadership has been central to managing the company's resources and personnel, ensuring the continuity of its specialized diagnostic services amidst challenging market conditions.
RGDXQ OTC Market Information
Response Genetics, Inc. (RGDXQ) trades on the 'OTC Other' tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike stocks listed on major exchanges like NYSE or NASDAQ, 'OTC Other' companies are not required to meet minimum financial standards or file regular reports with the SEC. This tier often includes companies that are financially distressed, in bankruptcy, or have limited public information. Investors face significant challenges in obtaining reliable financial data and assessing the true operational status of such entities, leading to higher risk and uncertainty compared to higher OTC tiers or exchange-listed stocks.
- OTC Tier: OTC Other
- Extreme lack of transparency due to minimal or unknown disclosure requirements, making fundamental analysis nearly impossible.
- High potential for financial distress, bankruptcy, or delisting, as indicated by the 'OTC Other' tier and negative profit margin.
- Limited or no analyst coverage and institutional interest, leading to highly inefficient pricing and illiquidity.
- Significant price volatility and susceptibility to manipulation due to low trading volume and lack of regulatory oversight.
- Challenges in obtaining accurate and timely information about company operations, management, and financial health.
- Verify any available financial statements or disclosures directly from the company or OTC Markets website, if present.
- Research any news or regulatory filings related to restructuring, bankruptcy proceedings, or changes in business operations.
- Assess the current operational status and any ongoing business activities, as the 'OTC Other' tier often signifies inactive companies.
- Investigate management's background, track record, and any recent changes in leadership.
- Understand the company's capital structure, outstanding shares, and any potential dilution risks.
- Evaluate the current market for its products/services and the competitive landscape, if the business is still active.
- Consult with a financial advisor experienced in highly speculative OTC securities before considering any investment.
- Continued mention of an active business description focusing on pharmacogenomic tests for cancer.
- Identified CEO (Thomas Bologna) and stated employee count (96), suggesting some level of ongoing operation.
- Stated global presence in the United States and Europe, indicating established infrastructure.
- Commitment to expanding diagnostic offerings, implying future-oriented business plans.
- Serving a diverse client base including oncologists, hospitals, and pharmaceutical enterprises.
RGDXQ Healthcare Stock FAQ
What revenue streams does Response Genetics, Inc have in healthcare?
Response Genetics, Inc. generates revenue primarily through its specialized pharmacogenomic testing services within the oncology sector. The core revenue stream comes from the provision of its ResponseDX suite of diagnostic tests, which are utilized to guide cancer treatment decisions across various tumor types.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Word count for growth opportunities and FAQ answers was challenging due to limited source data for a distressed OTC company. Elaborations were made based on the stated business description and general industry context without speculation.